0000000000660380
AUTHOR
C Tamburino
Chronic total occlusions: A European global perspective
Treatment of chronic total occlusion (CTO) lesions still represents the last frontier for the interventionalist. Although the most important cause of procedural failure is the inability to cross the occlusion with the guide wire and to reach the distal true lumen end, other factors may prevent balloon crossing and final recanalisation. Moreover, the recurrence rate of restenosis and reocclusion is higher compared with other subsets of lesions. Data obtained over the past decade have shown that successful recanalisabon of CTO provides long-term outcome improvement, left ventricular ejection fraction improvement, electrical stability of myocardium and improved tolerance for future coronary ev…
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: A multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment
AIMS Our aim was to compare, in a large unprotected left main coronary artery (ULMCA) all-comer registry, the long-term clinical outcome after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in patients with acute coronary syndrome (ACS). METHODS AND RESULTS Of a total of 2,775 patients enrolled in the Drug Eluting Stents for Left Main Coronary Artery Disease (DELTA) multicentre registry, 379 (13.7%) patients with ACS treated with PCI (n=272) or CABG (n=107) were analysed. Baseline demographics were considerably different in the two groups before propensity matching. No significant differences emerged for…
Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
OBJECTIVE - It is still controversial whether sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) are equally effective in patients with diabetes. In these patients, multiple individual variables may be responsible for neointimal hyperplasia, thus making difficult the comparison of the two drug-eluting stents (DES). RESEARCH DESIGN AND METHODS - We designed a prospective, randomized study to compare the efficacy in prevention of restenosis of SES and PES, both implanted in the same diabetic patient with multiple de novo coronary artery lesions undergoing elective percutaneous coronary intervention. We enrolled 60 patients with diabetes with at least two significant de novo angi…